Street Calls of the Week
Investing.com - Piper Sandler has reiterated an Overweight rating and $190.00 price target on Align Technology (NASDAQ:ALGN), currently trading at $137.12, citing improved clear aligner volumes in September. According to InvestingPro, the company maintains a "GOOD" overall financial health score, with strong profitability metrics.
September clear aligner volumes increased 3.3% (or decreased by a low single-digit percentage when adjusted for the extra day), bringing the full quarter volumes to -1.2% overall, according to Piper Sandler.
The research firm noted that performance for teen aligners showed improvement, both on an absolute basis and relative to braces and wires, giving September "some much-needed uniformity of improvement in the data."
With September data ending the third quarter on a positive note, Piper Sandler expressed increased confidence in Align Technology’s potential to meet or beat Wall Street’s third-quarter estimates.
The firm acknowledged investor skepticism following last quarter when positive industry data points did not translate to strong results, but stated it prefers this combination along with the stock’s "cheap valuation" as a solid long-term investment opportunity.
In other recent news, Align Technology has been the subject of several notable developments. UBS has lowered its price target for Align Technology to $155, maintaining a Neutral rating due to growth concerns following disappointing second-quarter results. Similarly, Mizuho has reduced its price target from $210 to $170 but continues to hold an Outperform rating, forecasting third-quarter 2025 revenues of $985 million, slightly above the Street’s estimate. Jefferies has downgraded Align Technology from Buy to Hold, citing concerns about market penetration and reducing its price target to $140.
In legal matters, Align Technology has filed a complaint with the U.S. International Trade Commission against Angelalign Technology over alleged patent infringements. The complaint seeks to block the importation and sale of infringing products in the United States. Piper Sandler has maintained an Overweight rating with a $190 price target amid the ongoing patent litigation, which spans the U.S., Europe, and China. These recent developments reflect a mix of financial forecasts and legal strategies impacting Align Technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.